Registered title, quoted from ClinicalTrials.gov
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteNanjing Tianyinshan Hospital南京天印山医院NanjingHospital page
- Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07861425, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathologically confirmed HCC
Inclusion criterion 3
ECOG Performance Score of 0 or 1
Inclusion criterion 6
Presence of at least 1 measurable lesion per RECIST 1.1
Inclusion criterion 5
History of another malignancy within the past 5 years
Exclusion criterion 2
Active syphilis infection and HIV infection
Exclusion criterion 11
Pregnancy or breast-feeding women
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07861425, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Males or females aged 18 to 75 years
- HCC that is unresectable or metastatic
- Pathologically confirmed HCC
- Barcelona Clinic Liver Cancer (BCLC) stage B or C
- Presence of at least 1 measurable lesion per RECIST 1.1
- ECOG Performance Score of 0 or 1
- Life expectancy of at least 3 months for the dose escalation portion and of at least 6 months for the dose expansion portion
- Adequate bone marrow reserve
- Adequate renal function
- Adequate hepatic function
- Left ventricular ejection fraction (LVEF) ≥50%
- Ability to fully understand the investigational nature of this study
- Agreement to contraception requirements
Exclusion Criteria:
- Other types of hepatic malignancies, such as mixed cholangiocarcinoma/HCC, sarcomatoid HCC, or fibrolamellar HCC,
- History of another malignancy within the past 5 years
- Ascites that requires non-pharmacologic intervention (e.g., paracentesis)
- History of hepatic encephalopathy within 12 months
- History of (non-infectious) ILD/pneumonitis
- History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies or known sensitivity or allergy to any components of ACE723.
- History of bleeding events (including hematemesis or melena)
- Active CNS metastases
- Unresolved toxicities from prior anticancer therapy
- Clinically significant active infection
- Active syphilis infection and HIV infection
- Pregnancy or breast-feeding women
- Uncontrolled intercurrent illness
- History of known substance abuse or illicit drug use
- Poor compliance
Quoted from ClinicalTrials.gov, NCT07861425, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07861425, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.